A study shows that high levels of negatively charged lipids can lock growth receptors into an overactive state, driving ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations ...

Cohort 1, osimertinib monotherapy. Cohort 2, a combination of osimertinib and savolitinib therapy. The cutoff date: May 28, 2024. FAS, Full Analysis Set; PD, Progressive disease. [1] Patients with MET ...

Scientists have discovered that increased expression of a novel long non-coding RNA drives glioblastoma cell growth alongside ...

CStone Pharmaceuticals ('CStone,' HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...

The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The project, "A novel ...